The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

She brings her global experience across multiple therapeutic areas to her current role leading operations at YPrime. In this ...

The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, ...

Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have ...

Applying AI-enabled route scouting services allows drug developers to avoid pitfalls that can typically occur in drug ...

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal ...

Clinical trials are becoming increasingly complex as emerging technologies such as immunotherapy enter the mainstream.

Motif, a fast-growing company in the clinical research technology sector, has taken a significant step in expanding its ...

In an in-depth conversation, OSP senior editor, Liza Laws, interviews Adrian Kizewski, associate director at IQVIA, to ...